Joal D Beane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4387824/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 2278-2288.	7.0	310
2	Robotic distal pancreatectomy: Cost effective?. Surgery, 2010, 148, 814-823.	1.9	225
3	Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial. Annals of Surgical Oncology, 2014, 21, 2484-2489.	1.5	180
4	Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 75, 1271-1283.	3.7	162
5	Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. Journal of Surgical Oncology, 2014, 110, 275-284.	1.7	159
6	Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy. Annals of Surgery, 2016, 264, 344-352.	4.2	144
7	Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 143-149.	4.2	142
8	Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy. Annals of Surgery, 2018, 267, 608-616.	4.2	117
9	500 Minimally Invasive Robotic Pancreatoduodenectomies. Annals of Surgery, 2021, 273, 966-972.	4.2	112
10	The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy. Journal of Gastrointestinal Surgery, 2016, 20, 262-276.	1.7	108
11	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	8.2	88
12	Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy. Annals of Surgery, 2017, 265, 978-986.	4.2	88
13	Establishing a Quantitative Benchmark for Morbidity in Pancreatoduodenectomy Using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity Index. Annals of Surgery, 2015, 261, 527-536.	4.2	73
14	Splenic Preserving Distal Pancreatectomy: Does Vessel Preservation Matter?. Journal of the American College of Surgeons, 2011, 212, 651-657.	0.5	55
15	Variation in Drain Management After Pancreatoduodenectomy. Annals of Surgery, 2019, 269, 718-724.	4.2	54
16	Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. Surgery, 2011, 150, 844-853.	1.9	53
17	Robotic pancreatoduodenectomy with vascular resection: Outcomes and learning curve. Surgery, 2019, 166, 8-14.	1.9	52
18	Optimal Pancreatic Surgery. Annals of Surgery, 2021, 274, e355-e363.	4.2	48

JOAL D BEANE

#	Article	IF	CITATIONS
19	Distal pancreatectomy with celiac axis resection: what are the added risks?. Hpb, 2015, 17, 777-784.	0.3	46
20	The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Annals of Surgery, 2019, 270, 147-157.	4.2	43
21	Assessing the impact of conversion on outcomes of minimally invasive distal pancreatectomy and pancreatoduodenectomy. Hpb, 2018, 20, 356-363.	0.3	42
22	Identification of an Optimal Cut-off for Drain Fluid Amylase on Postoperative Day 1 for Predicting Clinically Relevant Fistula After Distal Pancreatectomy. Annals of Surgery, 2019, 269, 337-343.	4.2	42
23	Pancreatoduodenectomy with venous or arterial resection: a NSQIP propensity score analysis. Hpb, 2017, 19, 254-263.	0.3	35
24	ls American College of Surgeons NSQIP Organ Space Infection a Surrogate for Pancreatic Fistula?. Journal of the American College of Surgeons, 2014, 219, 1111-1116.	0.5	33
25	Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). Journal of Medical Genetics, 2019, 56, 370-379.	3.2	33
26	Defining the post-operative morbidity index for distal pancreatectomy. Hpb, 2014, 16, 915-923.	0.3	32
27	Optimal management of delayed gastric emptying after pancreatectomy: An analysis of 1,089 patients. Surgery, 2014, 156, 939-948.	1.9	31
28	Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers, 2021, 13, 5333.	3.7	29
29	Dimethylamino Parthenolide Enhances the Inhibitory Effects of Gemcitabine in Human Pancreatic Cancer Cells. Journal of Gastrointestinal Surgery, 2012, 16, 1333-1340.	1.7	26
30	Quantifying the Burden of Complications Following Total Pancreatectomy Using the Postoperative Morbidity Index: A Multi-Institutional Perspective. Journal of Gastrointestinal Surgery, 2015, 19, 506-515.	1.7	24
31	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery, 2021, 169, 708-720.	1.9	22
32	Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 2018, 22, 68-76.	1.7	19
33	The model for end-stage liver disease predictsÂoutcomes in patients undergoing cholecystectomy. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 5192-5200.	2.4	16
34	Small pancreatic neuroendocrine tumors: Resect or enucleate?. American Journal of Surgery, 2021, 222, 29-34.	1.8	16
35	Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer. Journal of Translational Medicine, 2017, 15, 92.	4.4	14
36	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery, 2021, 170, 1195-1204.	1.9	11

JOAL D BEANE

#	Article	IF	CITATIONS
37	Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes. Journal of the American College of Surgeons, 2022, 234, 436-443.	0.5	11
38	p85Ĵ² regulatory subunit of class IA PI3 kinase negatively regulates mast cell growth, maturation, and leukemogenesis. Blood, 2012, 119, 3951-3961.	1.4	10
39	Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study. Investigational New Drugs. 2015. 33. 109-118.	2.6	9
40	Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Surgery, 2015, 158, 881-889.	1.9	9
41	Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2019, 26, 1429-1436.	1.5	7
42	Vascular challenges from pancreatoduodenectomy in the setting of coeliac artery stenosis. BMJ Case Reports, 2017, 2017, bcr2016217943.	0.5	3
43	Novel Techniques and the Future of HIPEC (Immunotherapy, Viral Therapy). , 2020, , 221-234.		1
44	ASO Author Reflections: Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 2019, 26, 581-582.	1.5	0
45	Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. American Journal of Surgery, 2021, 222, 570-576.	1.8	0
46	Real-time mortality risk calculator following pancreatoduodenectomy: quantifying the impact of perioperative events. Hpb, 2022, , .	0.3	0
47	The Role of AKT in Soft Tissue Sarcoma: Review and Insights. Molecular Cancer Research, 0, , .	3.4	0